Lederfolin

Gastric Cancer

University of PisaDormant

D

28/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 65/ 100

Competitive context

283 Active assets in the Gastric Cancer cohort.

Asset / Sponsor	Phase	Rating
Rivoceranib Jiangsu Hansoh Pharmaceutical Co., Ltd.	Phase 4	BBB
FLUOROURACILUM I-Mab Biopharma US Limited	Phase 4	BB
Eloxatin Qilu Pharmaceutical Co., Ltd.	Phase 3	BB
Pembrolizumab Eikon Therapeutics	Phase 3	BB
Epirubicin Rondo Therapeutics	Phase 3	BB

View all 50 →

Same molecule, other indications

Lederfolin is also rated in:

colon carcinomaDormant

CCC

Indicative ·

54 / 100

colorectal cancerDormant

D

Indicative ·

30 / 100

gallbladder cancerDormant

D

Indicative ·

30 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.